%0 Journal Article
%T Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial
%A Binghe Xu
%A Changwu Ma
%A Chunhong Hu
%A Jie Li
%A Jifeng Feng
%A Jing Huang
%A Junxing Huang
%A Lin Wu
%A Lu Wen
%A Ping Lu
%A Qingxia Fan
%A Shu Zhang
%A Xi Wang
%A Xianglin Yuan
%A Yi Ba
%A Ying Cheng
%A Ying Liu
%A Yuxian Bai
%J Archive of "Cancer Communications".
%D 2019
%R 10.1186/s40880-019-0359-7
%X The online version of this article (10.1186/s40880-019-0359-7) contains supplementary material, which is available to authorized users
%K Esophageal squamous cell carcinoma
%K Recurrent
%K Metastasis
%K Multicenter
%K open-label
%K randomized trial
%K Irinotecan
%K S-1
%K Overall survival
%K Progression-free survival
%K Objective response rate
%K Disease control rate
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444575/